US4070462A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Steroid ointment
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1976-10-26
•
Granted: 1978-01-24
•
Expires: 1996-10-26
Abstract
Abstract An improved ointment for the topical administration of steroids is comprised of a therapeutically effective amount of a 17-mono or 17,21-diester of betamethasone in a non-aqueous base comprised of 5-15% of a glycol solvent, 1-3% of a principle emulsifying agent; 0-7% of a secondary emulsifying agent; and 70-90% of a petrolatum base.
Inventors
- 👤 Varda Ecker
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 04:06
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K31/00; A61K31/56; A61K31/57; A61P; A61P29/00; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/14
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
81 words
A method of treating inflammation which comprises applying to the skin a topical formulation comprising an amount effective to treat said inflammation of a dermatologically acceptable anti-inflammatory 17-mono or 17,21-diester of betamethasone in a non-aqueous, water-miscible solvent-in-oil base comprising - 15% of a non-aqueous, water-miscible solvent consisting essentially of a glycol solvent selected from the group consisting of 1,2-propylenediol, butylene glycol, hexylene glycol and mixtures thereof; 1-3% of propylene glycol monostearate; 0-7% of white or yellow wax; and 70-90% of petrolatum.
Claim 2
Independent Claim
81 words
A method of treating inflammation which comprises applying to the skin a topical formulation comprising an amount effective to treat said inflammation of a dermatologically acceptable anti-inflammatory 17-mono or 17,21-diester of betamethasone in a non-aqueous, water-miscible solvent-in-oil base comprising - 15% of a non-aqueous, water-miscible solvent consisting essentially of a glycol solvent selected from the group consisting of 1,2-propylenediol, butylene glycol, hexylene glycol and mixtures thereof; 1-3% of propylene glycol monostearate; 0-7% of white or yellow wax; and 70-90% of petrolatum.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein the 17-mono or 17,21-diester of betamethasone is betamethasone 17,21-dipropionate.
Claim 4
Dependent Claim
15 words
The method of claim 1 wherein the 17-mono or 17,21-diester of betamethasone is betamethasone valerate.
Claim 5
Dependent Claim
21 words
The method of claim 1 wherein the 17-mono or 17,21-diester of betamethasone is present in an amount of 0.01-0.2% by weight.
Claim 6
Dependent Claim
11 words
The method of claim 1 wherein the glycol solvent is 1,2-propylenediol.
Claim 7
Dependent Claim
11 words
The method of claim 1 wherein the wax is white wax.
Claim 8
Dependent Claim
75 words
A topical ointment for the treatment of inflammation which comprises an amount effective to treat said inflammation of a dermatologically acceptable anti-inflammatory 17-mono or 17,21-diester of betamethasone in a non-aqueous, water-miscible solvent-in-oil base comprising 5-15% of a non-aqueous, water-miscible solvent consisting essentially of a glycol solvent selected from the group consisting of 1,2-propylenediol, butylene glycol, hexylene glycol and mixtures thereof; 1-3% of propylene glycol monostearate; 0-7% of white or yellow wax; and 70-90% of petrolatum.
Claim 9
Dependent Claim
75 words
A topical ointment for the treatment of inflammation which comprises an amount effective to treat said inflammation of a dermatologically acceptable anti-inflammatory 17-mono or 17,21-diester of betamethasone in a non-aqueous, water-miscible solvent-in-oil base comprising 5-15% of a non-aqueous, water-miscible solvent consisting essentially of a glycol solvent selected from the group consisting of 1,2-propylenediol, butylene glycol, hexylene glycol and mixtures thereof; 1-3% of propylene glycol monostearate; 0-7% of white or yellow wax; and 70-90% of petrolatum.
Claim 10
Dependent Claim
15 words
The ointment of claim 7 wherein the 17-mono or 17,21-diester of betamethasone is betamethasone 17,21-dipropionate.
Claim 11
Dependent Claim
15 words
The ointment of claim 7 wherein the 17-mono or 17,21-diester of betamethasone is betamethasone 17-valerate.
Claim 12
Dependent Claim
21 words
The ointment of claim 7 wherein the 17-mono or 17,21-diester of betamethasone is present in an amount of 0.01-0.02% by weight.
Claim 13
Dependent Claim
11 words
The ointment of claim 7 wherein the glycol solvent is 1,2-propylenediol.
Claim 14
Dependent Claim
11 words
The ointment of claim 7 wherein the wax is white wax.
Claim 15
Dependent Claim
16 words
A method of treating psoriasis which comprises applying to the skin an ointment of claim 7.
Claim 16
Dependent Claim
16 words
A method of treating psoriasis which comprises applying to the skin an ointment of claim 8.
Claim 17
Dependent Claim
16 words
A method of treating psoriasis which comprises applying to the skin an ointment of claim 9.
Claim 18
Dependent Claim
16 words
A method of treating psoriasis which comprises applying to the skin an ointment of claim 10.
Claim 19
Dependent Claim
16 words
A method of treating psoriasis which comprises applying to the skin an ointment of claim 11.
Claim 20
Dependent Claim
16 words
A method of treating psoriasis which comprises applying to the skin an ointment of claim 12.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-01-23 | 1981-07-25 | 1982-01-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-01-23 | 1985-07-25 | 1986-01-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-01-23 | 1989-07-25 | 1990-01-24 | $7700.00 | Window Closed / Lapsed |